BioSpace News Archive

Allogene Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ALLO-605, the Company’s next-generation AlloCAR T therapy targeting BCMA for the treatment of relapsed or refractory multiple myeloma.

electroCore, Inc. today announced the pricing of an underwritten public offering of 18,000,000 shares of its common stock at a public offering price of $1.00 per share.

Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that David K. Erickson has joined the company as Vice President, Investor Relations where he will be responsible for developing, implementing and managing a comprehensive and strategic investor relations program.

SELLAS Life Sciences Group, Inc today announced promising updated clinical data and initial immunobiological data from its Phase 1/2 clinical trial with its lead asset, galinpepimut-S (GPS), the Company’s Wilms Tumor-1 (WT1)-targeting peptide immunotherapeutic, in combination with the checkpoint inhibitor pembrolizumab (Keytruda®).

Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received approval by the Central Adelaide Local Health Network Human Research Ethics Committee to commence a clinical trial of Cynata’s Cymerus™ mesenchymal stem cell product in patients with diabetic foot ulcers.

Susan G. Komen today announced the awarding of 30 new grants to researchers at 18 leading institutions in the U.S. and Canada.

BioSig Technologies, Inc., a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced that physicians have completed 1000 patient cases with its technology across nine installation sites.

Letco Medical, LLC (Letco Med), is pleased to announce its three-year financial commitment of over $100,000 to fund the Alliance for Pharmacy Compounding (APC) nationwide advocacy campaign.

INVO Bioscience, Inc. (NASDAQ: INVO), INVOcell®, today announced the signing of a joint venture agreement in partnership with reproductive specialist Dr. Sue Ellen Carpenter, M.D. through its wholly-owned subsidiary, INVO Centers, LLC, to open an INVO clinic in Atlanta.

Today, Strand Therapeutics, announced Jake Becraft, PhD, co-founder and CEO of Strand, has been named to MIT Technology Review’s prestigious annual list of Innovators Under 35.